

Health Care/Finland, May 20, 2019 Company update

CMD notes

Pihlajalinna hosted the 2019 CMD last Friday. The focus of the event was on increased health and social care costs, cooperation of private and public sectors as well as the digitalization of health care. Pihlajalinna did not make any changes to its '19E guidance nor its long-term financial targets. We maintain our rating "Buy" with TP of EUR 13.

Need of new solutions for arranging services

The finances of Finnish municipalities have continued to deteriorate and municipalities are forced to find new solutions to balance their increased health and social care costs. Cooperation with private sector is no longer purely voluntary. As Pihlajalinna stated in Ω 1, municipalities' activity has increased after the failure of the SOTE reform, despite of the restriction law.

New opportunities on occupational healthcare


Pihlajalinna has been able to use its network to expand services across the country. The company sees opportunities in expanding its occupational healthcare network as municipalities and other public sector entities are interested in divesting the occupational healthcare providers they currently own. The company targets to expand in basic-level specialized care and non-urgent specialized care as the public sector has made cuts in operations and centralized specialized care in fewer units.

Focusing on profitability improvements in 2019E

Pihlajalinna's plan is to improve its profitability by organic growth, increasing cross-selling, and by addressing profitability issues in the new medical service centers. Pihlajalinna will also improve its customer service experience by bringing new digital solutions to the market, which will also be a significant profitability driver in the future.

Guidance for 2019E intact

Pihlajalinna reiterated its guidance for 2019E; to increase its revenue and EBIT in 2019E from 2018 levels. The company did not make changes to its long-term targets and expects EBIT % of 7% in long-term. We keep our estimates intact. We maintain our rating "Buy" with TP of EUR 13.



■ BUY □ HOLD ■ SELL

KEY FIGL	IRES										
	Sales EURm	EBIT EURm	EBIT %	Ptx profit EURm	EPS EUR	P/E (x)	EV/Sales (x)	P/CF (x)	EV/EBIT (x)	DPS EUR	
2017	424	20	4.7%	19	0.52	25.7	0.8	7.2	16.2	0.16	
2018	488	14	2.9%	10	0.19	46.4	0.8	4.4	27.9	0.10	
2019E	525	24	4.5%	20	0.64	17.4	0.8	4.4	18.0	0.21	
2020E	535	25	4.6%	20	0.66	16.9	0.7	4.0	16.4	0.22	
2021E	549	29	5.2%	25	0.82	13.5	0.6	4.1	12.3	0.27	
Market ca	p, EURm		251 E	251 BV per share 2019E, EUR			5.9 CAGR EPS 2018-21, %				
Net debt 2	.019E, EURm		162 F	Price/book 2019l			1.9 CAGR s	sales 2018-	21, %	4.0	
Enterprise	value, EURm		430 [Dividend yield 20		1.9 ROE 20)19E, %		11.3		
Total asset	s 2019E, EURr	n	428 1	ax rate 2019E, o	/ o		20.6 ROCE 2019E, %				
Goodwill 2	2019E, EURm		170 E	Equity ratio 2019	9E, %		33.4 PEG, P/E 19/CAGR				

Health Care/Finland, May 20, 2019 Company update

Estimates

Net sales	2017	Q1'18	Q2'18	Q3'18	Q4'18	2018E	Q1'19E	Q2'19E	Q3'19E	Q4'19E	2019E	2020E
Corporate Customers	82,6	26,2	25,3	22,8	29,4	103,7	31,6	27,8	26,5	31,9	117,8	120,1
of which insurance companies	26,6	6,6	6,6	5,3	6,7	25,2	7,1	7,1	7,1	7,1	28,4	29,0
of which other corporates	56,0	19,6	18,7	17,5	22,7	78,5	24,5	20,7	19,4	24,8	89,4	91,2
Private Customers	67,9	22,2	24,3	21,0	24,6	92,1	26,5	25,3	22,0	25,7	99,5	101,5
Public sector customers	330,5	85,1	90,3	85,7	88,6	349,7	89,3	94,6	89,9	92,9	366,7	374,0
Total	424,0	119,3	125,3	116,3	126,9	487,8	132,5	132,8	125,0	134,4	524,7	535,2
Net sales growth												
Corporate Customers	-	17,0%	21,1%	25,3%	39,3%	25,5%	20,6%	9,8%	16,4%	8,4%	13,6%	2,0%
Private Customers	-	16,8%	35,0%	54,4%	42,2%	35,6%	19,4%	4,1%	4,9%	4,5%	8,1%	2,0%
Public sector customers	-	2,5%	9,9%	6,1%	4,9%	5,8%	4,9%	4,8%	4,9%	4,8%	4,9%	2,0%
Total	6,2%	8,5%	17,5%	17,0%	17,5%	15,0%	11,1%	6,0%	7,5%	5,9%	7,6%	2,0%
Adj. EBITDA (group)	34,0	6,9	10,2	14,2	14,6	45,9	12,6	13,1	16,0	16,8	58,6	61,5
Adj. EBITDA-margin (group	8,0%	5,8%	8,1%	12,2%	11,5%	9,4%	9,5%	9,9%	12,8%	12,5%	11,2%	11,5%

Source: Pihlajalinna, Evli Research

Valuation

On our estimates, Pihlajalinna trades at 7.3x and 5.9x EV/EBITDA multiples in 2019E-2020E, which translates into 26% and 29% discount compared to the peer group.

Secur	ity MCAP	EV/EBITDA	EV/EBITDA	EV/EBITDA	EV/EBIT	EV/EBIT	EV/EBIT	P/E	P/E	P/E
PIHLAJALINNA PEER GROUP identi	fier Local FX	19	20	21	19	20	21	19	20	21
Ambea AB AMBEA	-SE 4582	9,9x	8,1x	7,3x	22,6x	16,0x	14,0x	10,2x	9,0x	8,0x
Attendo AB ATT-S	SE 8164	9,0x	8,2x	7,5x	20,5x	17,7x	15,6x	21,6x	16,4x	13,4x
Cambian Group Plc CMBN-	-GB									
Capio AB CAPIO	-SE									
CareTech Holdings PLC CTH-C	GB 392	9,7x	8,3x	7,6x	11,8x	9,9x	8,6x	10,2x	8,4x	7,3x
Fresenius SE & Co. KGaA FRE-I	DE 27081	6,9x	6,2x	5,5x	9,6x	8,7x	7,9x	14,5x	13,6x	12,6x
Georgia Healthcare Group Plc GHG-	GB 134	8,6x	7,2x	5,9x	10,9x	8,7x	7,2x	19,8x	14,6x	11,5x
GHP Specialty Care AB GHP-	SE 901	6,7x	6,0x	5,6x	14,1x	12,5x	11,5x	19,7x	17,0x	17,4x
Humana AB HUM-	SE 2976	11,1x	9,8x	8,9x	14,4x	12,5x	11,3x	10,9x	9,7x	8,8x
Korian SA KORI-	FR 2957	11,1x	10,2x	9,4x	16,9x	15,3x	13,8x	21,7x	18,3x	15,8x
LNA Sante SA LNA-	FR 431	11,5x	10,7x	9,9x	13,5x	12,5x	11,6x	17,9x	16,2x	14,4x
Mediclinic International Plc MDC-	GB 2511	8,3x	7,6x	6,5x	12,3x	11,1x	8,6x	12,7x	11,1x	8,9x
Orpea SA ORP-	FR 6601	17,5x	16,4x	15,4x	24,6x	23,0x	21,6x	26,1x	23,3x	21,2x
RHON-KLINIKUM AG RHK-	DE 1710	13,9x	13,2x	13,3x	30,1x	28,0x	31,1x	43,7x	39,2x	41,0x
Spire Healthcare Group PLC SPI-G	iB 485	8,1x	7,4x	7,6x	17,9x	15,6x	15,8x	23,5x	17,6x	14,3x
Terveystalo Oy Class A TTALO	-FI 1169	10,4x	9,5x	8,7x	20,2x	17,7x	15,1x	18,3x	16,2x	15,0x
Peer Group Median	4529	9,8x	8,3x	7,6x	15,6x	13,9x	12,7x	19,0x	16,2x	13,9x
Peer Group Average	2111	10,2x	9,2x	8,5x	17,1x	14,9x	13,8x	19,3x	16,5x	15,0x
Pihlajalinna (Evli est.)	251	7,3x	5,9x	5,2x	18,1x	16,4x	11,6x	17,4x	18,5x	12,9x

Pihlajalinna premium/discount to peer median

Health Care/Finland, May 20, 2019 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	11.08 PV of Free Cash Flow	255 Long-term growth, %	2.0 Risk-free interest rate, %	2.25
DCF share value	14.82 PV of Horizon value	280 WACC, %	7.0 Market risk premium, %	5.8
Share price potential, %	33.7 Unconsolidated equity	-17 Spread, %	0.5 Debt risk premium, %	2.8
Maximum value	17.0 Marketable securities	36 Minimum WACC, %	6.5 Equity beta coefficient	0.80
Minimum value	13.0 Debt - dividend	-219 Maximum WACC, %	7.5 Target debt ratio, %	20
Horizon value, %	52.3 Value of stock	335 Nr of shares, Mn	22.6 Effective tax rate, %	25

DCF valuation, EURm	2018	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	Horizon
Net sales	488	525	535	549	565	582	599	617	636	655	668	682
Sales growth, %	15.0	7.6	2.0	2.5	3.0	3.0	3.0	3.0	3.0	3.0	2.0	2.0
Operating income (EBIT)	14	24	25	29	29	32	33	34	35	33	33	34
EBIT margin, %	2.9	4.5	4.6	5.2	5.2	5.5	5.5	5.5	5.5	5.0	5.0	5.0
+ Depreciation+amort.	32	35	42	37	31	25	22	20	19	18	18	
- Income taxes	-5	-5	-5	-6	-6	-6	-7	-7	-7	-7	-7	
- Change in NWC	3	3	1	1	1	1	1	1	1	2	1	
NWC / Sales, %	-8.0	-8.0	-8.0	-8.0	-8.0	-8.0	-8.0	-8.0	-8.0	-8.0	-8.0	
+ Change in other liabs	-1	0	0	0	0	0	0	0	0	0	0	
- Capital Expenditure	-202	-32	-13	-14	-15	-16	-17	-18	-18	-18	-19	-19
Investments / Sales, %	41.3	6.0	2.4	2.5	2.7	2.7	2.8	2.9	2.8	2.7	2.8	2.8
- Other items	-1	0	0	0	0	0	0	0	0	0	0	
= Unlevered Free CF (FCF)	-159	25	50	47	41	36	33	30	30	27	27	539
= Discounted FCF (DFCF)		24	45	39	32	27	22	19	18	15	14	280
					•	•				•	•	
= DFCF min WACC		24	45	40	33	27	23	20	19	16	14	326
= DFCF max WACC		24	44	39	32	26	22	19	17	15	13	244

Health Care/Finland, May 20, 2019 Company update

INTERIM FIGURES

EVLI ESTIMATES, EURm	2018Q1	2018Q2	2018Q3	2018Q4	2018	2019Q1	2019Q2E	2019Q3E	2019Q4E	2019E	2020E	2021E
Net sales	119	125	116	127	488	133	133	125	134	525	535	549
EBITDA	7	10	14	15	46	13	13	16	17	58	67	65
EBITDA margin (%)	5.6	8.1	12.1	11.6	9.3	9.4	9.9	12.8	12.5	11.1	12.5	11.9
EBIT	0	2	6	7	14	4	5	7	8	24	25	29
EBIT margin (%)	-0.3	1.5	5.1	5.1	2.9	2.9	3.4	5.8	6.0	4.5	4.6	5.2
Net financial items	-1	-1	-1	-1	-4	-1	-1	-1	-1	-4	-4	-4
Pre-tax profit	-1	1	5	5	10	3	4	6	7	20	20	25
Tax	0	0	-1	-1	-3	-1	-1	-1	-1	-4	-4	-5
Tax rate (%)	0.0	27.3	22.0	24.1	26.5	24.1	20.0	20.0	20.0	20.6	20.0	20.0
Net profit	-2	1	2	3	4	2	3	5	5	14	15	19
EPS	-0.08	0.04	0.10	0.13	0.19	0.08	0.11	0.21	0.24	0.64	0.66	0.82
EPS adjusted (diluted no. of shares)	-0.08	0.04	0.10	0.13	0.19	0.08	0.11	0.21	0.24	0.64	0.66	0.82
Dividend per share	0.00	0.00	0.00	0.00	0.10	0.00	0.00	0.00	0.00	0.21	0.22	0.27
SALES, EURm												
Corporate Customers	28	24	25	29	106	32	28	27	32	118	120	123
Private Customers	22	24	21	25	92	27	25	22	26	100	102	104
Public sector customers	84	92	84	89	348	89	95	90	93	367	374	383
Eliminations	-14	-15	-13	-16	-58	-15	-15	-13	-16	-59	-60	-62
Total	119	125	116	127	488	133	133	125	134	525	535	549
SALES GROWTH, Y/Y %												
Corporate Customers	23.7	13.9	36.3	39.3	28.0	14.1	16.7	7.0	8.4	11.4	2.0	2.5
Private Customers	16.8	35.0	<i>53.7</i>	42.2	35.5	19.4	4.1	5.4	4.5	8.2	2.0	2.5
Public sector customers	0.6	11.8	3.6	4.9	5.2	6.9	2.9	7.4	4.8	5.5	2.0	2.5
Eliminations	-1.4	1.4	-0.8	4.7	1.1	4.9	1.3	2.8	2.7	2.9	2.0	2.5
Total	8.4	17.5	17.0	17.6	15.0	11.2	6.0	7.5	5.9	7.6	2.0	2.5
EBIT, EURm										·	· ·	
Group	0	2	6	7	14	4	5	7	8	24	25	29
Total	0	2	6	7	14	4	5	7	8	24	25	29
EBIT margin, %			·									
Total	-0.3	1.5	5.1	5.1	2.9	2.9	3.4	5.8	6.0	4.5	4.6	5.2

Health Care/Finland, May 20, 2019 Company update

INCOME STATEMENT, EURm	2014	2015	2016	2017	2018	2019E	2020E	2021E
Sales	149	213	399	424	488	525	535	549
Sales growth (%)	42.6	43.3	87.0	6.2	15.0	7.6	2.0	2.5
Costs	-135	-201	-370	-390	-442	-466	-468	-483
Reported EBITDA	14	13	29	34	46	58	67	65
Extraordinary items in EBITDA	0	0	0	0	0	0	0	0
EBITDA margin (%)	9.3	6.0	7.4	8.1	9.3	11.1	12.5	11.9
Depreciation	-6	-8	-13	-14	-32	-35	-42	-37
EBITA	8	5	17	20	14	24	25	29
Goodwill amortization / writedown	0	0	0	0	0	0	0	0
Reported EBIT	8	5	17	20	14	24	25	29
EBIT margin (%)	5.4	2.2	4.2	4.7	2.9	4.5	4.6	5.2
Net financials	-3	-2	-1	-1	-4	-4	-4	-4
Pre-tax profit	5	2	15	19	10	20	20	25
Extraordinary items	-2	-1	-1	-1	-1	0	0	0
Taxes	-1	0	-3	-3	-3	-4	-4	-5
Minority shares	0	-1	-3	-5	-3	-1	-1	-1
Net profit	1	1	8	10	4	14	15	19
BALANCE SHEET, EURm								
Assets								
Fixed assets	47	69	67	83	184	181	152	129
% of sales	31	32	17	20	38	35	28	24
Goodwill	56	76	92	104	170	170	170	170
% of sales	38	36	23	25	35	32	32	31
Inventory	1	2	2	2	3	3	3	3
% of sales	1	1	1	1	1	1	1	1
Receivables	14	20	27	25	40	33	34	35
% of sales	10	9	7	6	8	6	6	6
Liquid funds	11	15	28	37	36	37	37	38
% of sales	7	7	7	9	7	7	7	7
Total assets	131	185	218	254	437	428	400	379
Liabilities		100	2.0	201		.20	100	0,0
Equity	10	93	101	106	130	143	153	166
% of sales		44	25	25	27	27	29	30
Deferred taxes	4	5	6	6	6	6	6	6
% of sales	3	2	1	1	1	1	1	1
Interest bearing debt	88	42	52	77	217	199	160	123
% of sales	59	20	13	18	45	38	30	22
Non-interest bearing current liabilities	27	42	55	62	80	76	78	80
% of sales	18	20	14	15	16	15	15	15
Other interest free debt	1	3	3	3	3	3	3	3
% of sales	1	1	1	1	1	1	1	1
Total liabilities	131	185	217	254	437	428	400	379
CASH FLOW, EURm								
+ EBITDA	14	13	29	34	46	58	67	65
- Net financial items	-3	-2	-1	-1	-4	-4	-4	-4
- Taxes	-1	0	-2	-4	-4	-4	-4	-5
- Increase in Net Working Capital	4	9	7	8	3	3	1	1
+/- Other	-2	-2	-4	-5	-4	-1	-1	-1
= Cash flow from operations	11	19	30	37	42	53	59	58
- Capex	-28	-48	-27	-41	-122	-32	-13	-14
- Acquisitions	0	0	0	0	-79	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Net cash flow	-17	-29	3	-4	-160	22	46	44
+/- Change in interest-bearing debt	46	-46	10	25	141	-18	-39	-37
+/- New issues/buybacks	-29	82	-1	-2	24	0	0	0
- Paid dividend	0	0	0	-3	-3	-2	-5	-5
+/- Change in loan receivables	0	1	1	0	-1	0	0	0
Change in cash	0	8	13	15	1	2	2	2
3	-	-	. =	• •	•	=	=	_

Health Care/Finland, May 20, 2019 Company update

256 27 286 213 13 5 2 2 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5 170.5 2.8	380 25 416 399 29 17 15 10 98 1.0 14.2 25.1 25.1 12.3 15.8 39.1	275 40 325 424 34 20 19 11 100 0.8 9.5 16.2 16.2 8.5 11.2	195 181 391 488 46 14 10 4 121 0.8 8.6 27.9 27.9 8.9 10.3	251 162 430 525 58 24 20 14 133 0.8 7.4 18.0 18.0 7.6	251 122 389 535 67 25 20 15 143 0.7 5.8 15.7 15.7 6.2	251 84 350 549 65 29 25 19 157 0.6 5.4 12.3 5.8
286 213 13 5 2 2 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5	416 399 29 17 15 10 98 1.0 14.2 25.1 25.1 12.3 15.8	325 424 34 20 19 11 100 0.8 9.5 16.2 16.2 8.5	391 488 46 14 10 4 121 0.8 8.6 27.9 27.9 8.9	430 525 58 24 20 14 133 0.8 7.4 18.0 18.0	389 535 67 25 20 15 143 0.7 5.8 15.7	350 549 65 29 25 19 157 0.6 5.4 12.3 12.3
213 13 5 2 2 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5	399 29 17 15 10 98 1.0 14.2 25.1 25.1 12.3 15.8	424 34 20 19 11 100 0.8 9.5 16.2 16.2 8.5	488 46 14 10 4 121 0.8 8.6 27.9 27.9 8.9	525 58 24 20 14 133 0.8 7.4 18.0 18.0	535 67 25 20 15 143 0.7 5.8 15.7 15.7	549 65 29 25 19 157 0.6 5.4 12.3 12.3
13 5 2 2 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5 170.5	29 17 15 10 98 1.0 14.2 25.1 25.1 12.3 15.8	34 20 19 11 100 0.8 9.5 16.2 16.2 8.5	46 14 10 4 121 0.8 8.6 27.9 27.9 8.9	58 24 20 14 133 0.8 7.4 18.0 18.0	67 25 20 15 143 0.7 5.8 15.7 15.7	65 29 25 19 157 0.6 5.4 12.3 12.3
5 2 2 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5 170.5	17 15 10 98 1.0 14.2 25.1 25.1 12.3 15.8	20 19 11 100 0.8 9.5 16.2 16.2 8.5	14 10 4 121 0.8 8.6 27.9 27.9 8.9	24 20 14 133 0.8 7.4 18.0 18.0	25 20 15 143 0.7 5.8 15.7 15.7	29 25 19 157 0.6 5.4 12.3 12.3
2 92 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5	1.0 98 1.0 14.2 25.1 25.1 12.3 15.8	19 11 100 0.8 9.5 16.2 16.2 8.5	10 4 121 0.8 8.6 27.9 27.9 8.9	20 14 133 0.8 7.4 18.0 18.0	20 15 143 0.7 5.8 15.7 15.7	25 19 157 0.6 5.4 12.3 12.3
2 92 1.3 22.5 60.8 60.8 13.4 28.6 170.5	1.0 98 1.0 14.2 25.1 25.1 12.3 15.8	0.8 9.5 16.2 16.2 8.5	0.8 8.6 27.9 27.9 8.9	0.8 7.4 18.0 18.0	15 143 0.7 5.8 15.7 15.7	19 157 0.6 5.4 12.3 12.3
92 1.3 22.5 60.8 60.8 13.4 28.6 170.5	1.0 14.2 25.1 25.1 12.3 15.8	0.8 9.5 16.2 16.2 8.5	0.8 8.6 27.9 27.9 8.9	0.8 7.4 18.0 18.0	0.7 5.8 15.7 15.7	0.6 5.4 12.3 12.3
1.3 22.5 60.8 60.8 13.4 28.6 170.5	1.0 14.2 25.1 25.1 12.3 15.8	0.8 9.5 16.2 16.2 8.5	0.8 8.6 27.9 27.9 8.9	0.8 7.4 18.0 18.0	0.7 5.8 15.7 15.7	0.6 5.4 12.3 12.3
22.5 60.8 60.8 13.4 28.6 170.5	1.0 14.2 25.1 25.1 12.3 15.8	0.8 9.5 16.2 16.2 8.5	0.8 8.6 27.9 27.9 8.9	0.8 7.4 18.0 18.0	0.7 5.8 15.7 15.7	0.6 5.4 12.3 12.3
22.5 60.8 60.8 13.4 28.6 170.5	14.2 25.1 25.1 12.3 15.8	9.5 16.2 16.2 8.5	8.6 27.9 27.9 8.9	7.4 18.0 18.0	5.8 15.7 15.7	5.4 12.3 12.3
22.5 60.8 60.8 13.4 28.6 170.5	14.2 25.1 25.1 12.3 15.8	9.5 16.2 16.2 8.5	8.6 27.9 27.9 8.9	7.4 18.0 18.0	5.8 15.7 15.7	5.4 12.3 12.3
60.8 60.8 13.4 28.6 170.5	25.1 25.1 12.3 15.8	16.2 16.2 8.5	27.9 27.9 8.9	18.0 18.0	15.7 15.7	12.3 12.3
60.8 13.4 28.6 170.5 170.5	25.1 12.3 15.8	16.2 8.5	27.9 8.9	18.0	15.7	12.3
13.4 28.6 170.5 170.5	12.3 15.8	8.5	8.9			
28.6 170.5 170.5	15.8			7.0		
170.5 170.5		11.2		8.5	6.7	6.2
170.5	33.1	25.7	46.4	17.4	16.9	13.5
	39.1	25.7	46.4	17.4	16.9	13.5
	3.9	23.7	1.6	1.9	1.7	1.6
1.2	1.0	0.6	0.4	0.5	0.5	0.5
						4.1
						13.6
						15.8
0.0	0.0	0.0	0.0	2.2	2.0	1.9
00.010	00.010	00.010	00.000	00.000	00.000	00.000
						22,620
						22,620
						0.82
						0.82
						2.51
						2.68
						11.10
						6.95
						-0.56
						0.27
						33.0
0.0	0.8	1.2	1.2	1.9	2.0	2.5
3.0	10.2	10.8	3.8	11.3	10.7	12.4
4.0	11.7	12.2	5.3	6.9	7.6	9.5
22.3	6.8	9.7	41.3	6.0	2.4	2.5
346.6	85.2	209.2	429.1	91.2	30.8	37.7
2.1	0.8	1.2	4.0	2.8	1.8	1.3
0.2	0.1	0.3	1.1	0.8	0.6	0.5
50.5	46.4	41.8	29.8	33.4	38.2	44.0
0.28	0.24	0.37	1.39	1.14	0.80	0.51
						3,879
						141,428
						7,354
	22.3 346.6 2.1 0.2 50.5	0.0 0.0 0.0 0.0 0.0 0.0 20,613 20,613 20,613 20,613 0.07 0.47 0.49 1.28 1.03 1.64 5.68 5.95 4.47 4.74 0.78 0.26 0.00 0.15 0.0 31.9 0.0 0.8 3.0 10.2 4.0 11.7 22.3 6.8 346.6 85.2 2.1 0.8 0.2 0.1 50.5 46.4 0.28 0.24 2,503 3,526 85,258 113,188	0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20,613 20,613 20,613 20,613 20,613 20,613 0.07 0.47 0.52 0.09 1.28 1.40 1.03 1.64 1.86 5.68 5.95 6.91 4.47 4.74 4.87 0.78 0.26 -0.17 0.00 0.15 0.16 0.0 31.9 30.8 0.0 0.8 1.2 3.0 10.2 10.8 4.0 11.7 12.2 22.3 6.8 9.7 346.6 85.2 209.2 2.1 0.8 1.2 0.2 0.1 0.3 50.5 46.4 41.8 0.28 0.24 0.37 2,503 3,526 3,879 85,258 113,188 109,307 <	ao ao ao ao ao ao ao<	0.0 0.0 0.0 0.0 20.4 0.0 0.0 0.0 0.0 20.4 0.0 0.0 0.0 0.0 20.4 0.0 0.0 0.0 20.4 0.0 0.0 0.0 22.2 20,613 20,613 22,620 22,620 0.07 0.47 0.52 0.19 0.64 0.49 1.28 1.40 1.67 2.23 1.03 1.64 1.86 1.94 2.50 5.68 5.95 6.91 13.76 13.48 4.47 4.74 4.87 5.36 5.90 0.78 0.26 -0.17 -2.15 -1.61 0.00 0.15 0.16 0.10 0.21 0.0 31.9 30.8 53.9 33.0 0.0 0.8 1.2 1.2 1.9 22.3 6.8 9.7 41.3 6.0 346.6 85.2	0.0 0.0 0.0 0.0 19.5 17.2 0.0 0.0 0.0 0.0 20.4 19.8 0.0 0.0 0.0 22 2.0 20,613 20,613 20,613 22,620 22,620 22,620 20,613 20,613 22,620 22,620 22,620 22,620 0.07 0.47 0.52 0.19 0.64 0.66 0.07 0.47 0.52 0.19 0.64 0.66 0.49 1.28 1.40 1.67 2.23 2.58 1.03 1.64 1.86 1.94 2.50 2.78 5.68 5.95 6.91 13.76 13.48 12.16 4.47 4.74 4.87 5.36 5.90 6.34 0.78 0.26 -0.17 -2.15 -1.61 -1.17 0.00 0.15 0.16 0.10 0.21 0.22 0.0 31.9 30.8

Health Care/Finland, May 20, 2019 Company update

COMPANY DESCRIPTION:

INVESTMENT CASE:

OWNERSHIP STRUCTURE	SHARES	EURm	%
Lähitapiola Keskinäinen Vakuutusyhtiö	3,481,641	38.577	15.4%
Mww Yhtiö Oy	2,309,010	25.584	10.2%
Fennia Mutual Insurance Company	1,998,965	22.149	8.8%
Tapiola Keskinäinen Henkivakuutusyhtiö	1,891,865	20.962	8.4%
Elo Pension Company	1,267,161	14.040	5.6%
Niemistö Leena Katriina	703,475	7.795	3.1%
Fondita Nordic Micro Cap	550,000	6.094	2.4%
Ilmarinen Mutual Pension Insurance Company	490,000	5.429	2.2%
Fennia Life Insurance Company Ltd	270,759	3.000	1.2%
Nordea Pro Finland Fund	241,920	2.680	1.1%
Ten largest	13,204,796	146.309	58%
Residual	9,415,339	104.322	42%
Total	22,620,135	250.631	100%

EARNINGS CALENDAR	
August 15, 2019	Q2 report
November 05, 2019	Q3 report
OTHER EVENTS	

COMPANY MISCELLAN	LUIC	

CEO: Joni Aaltonen Kehräsaari B, 33200 Tampere

CFO: Ville Lehtonen

IR: Taina Erkkilä

Health Care/Finland, May 20, 2019 Company update

DEFINITIONS

P/E Price per share Earnings per share	EPS Profit before extraordinary items and taxes - income taxes + minority interest Number of shares			
P/Sales Market cap Sales	DPS Dividend for the financial period per share			
P/BV Price per share Shareholders' equity + taxed provisions per share	CEPS Gross cash flow from operations Number of shares			
P/CF Price per share Operating cash flow per share	EV/Share Enterprise value Number of shares			
EV (Enterprise value) Market cap + net debt + minority interest at market value – share of associated companies at market value	Sales/Share Sales Number of shares			
Net debt Interest bearing debt — financial assets	EBITDA/Share Earnings before interest, tax, depreciation and amortisation Number of shares			
Ev/Sales Enterprise value Sales	EBIT/Share Operating profit Number of shares			
Enterprise value Earnings before interest, tax, depreciation and amortisation	EAFI/Share Pretax profit Number of shares			
Enterprise value Operating profit	Capital employed/Share Total assets – non interest bearing debt Number of shares			
Div yield, % Dividend per share Price per share	Total assets Balance sheet total			
Payout ratio, % Total dividends Earnings before extraordinary items and taxes – income taxes + minority interest	Interest coverage (x) Operating profit Financial items			
Net cash/Share Financial assets — interest bearing debt Number of shares	Asset turnover (x) Turnover Balance sheet total (average)			
ROA, % Operating profit + financial income + extraordinary items Balance sheet total - interest free short term debt - long term advances received and accounts payable (average)	Debt/Equity, % Interest bearing debt Shareholders' equity + minority interest + taxed provisions			
ROCE, % Profit before extraordinary items + interest expenses + other financial costs Balance sheet total — noninterest bearing debt(average)	Equity ratio, % Shareholders' equity + minority interest + taxed provisions Total assets – interest free loans			
ROE, % Profit before extraordinary items and taxes – income taxes Shareholders' equity + minority interest + taxed provisions (average)				

PIHI A JAI INNA

Health Care/Finland, May 20, 2019 Company update

Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at https://research.evli.com/JasperAllModels.action?authParam=key;461EtauthParam=x;G3rNagWrtf7KEtauthType=3

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 timer per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 1st of February 2019. If recommendation is not given, it is not mentioned here.

Name(s) of the analyst(s): Rissanen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [20.05.2019, 8:30]. This report has been published on [20.05.2019, 9:15].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP may pursue an assignment from the issuer(s) of the financial instruments mentioned in the recommendation or this report. These assignments may have a limited economic or financial impact on ERP and/or Evli. Under such assignments ERP may perform services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or EVII. Under the assignment ERP performs services including, but not limited to,

EVLI EQUITY RESEARCH

PIHLAJALINNA

Health Care/Finland, May 20, 2019 Company update

arranging investor meetings or -events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Health Care/Finland, May 20, 2019 Company update

Contact information SALES, TRADING AND RESEARCH

Equity Sales		Trading		ETFs and Derivatives	
Ari Laine Lauri Ahokanto Niclas Henelius	+358 9 4766 9115 +358 9 4766 9117 +358 9 4766 9116	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi	+358 9 4766 9130 +358 9 4766 9120 +358 9 4766 9120	Tobias Björk (Head) Joachim Dannberg Kimmo Lilja Sami Järvinen	+358 9 4766 9130 +358 9 4766 9123 +358 9 4766 9130 +358 9 4766 9110
Structured Investments		Equity Research			
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Anna-Liisa Rissanen	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 157 9919		
Evli Investment Solutions					
Johannes Asuja Markku Reinikainen	+358 9 4766 9205 +358 9 4766 9669				



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001